Michelle Mollica on Individualizing Care Plans for Cancer Survivors

Name: Michelle Mollica on Individualizing Care Plans for Cancer Survivors
Uploaded: 2022-04-29T00:03:14.270Z
Description: Michelle Mollica, PhD, MPH, RN, OCN, of the National Cancer Institute, discusses how childhood cancer survivors may face different challenges than adult or geriatric patients.

April 28, 2022

Michelle Mollica, PhD, MPH, RN, OCN

Video

Conferences|ONS Annual Congress

Michelle Mollica, PhD, MPH, RN, OCN, of the National Cancer Institute, discusses how childhood cancer survivors may face different challenges than adult or geriatric patients.

Childhood cancer survivors may face different challenges than adult or geriatric patients, according to Michelle Mollica, PhD, MPH, RN, OCN, of the National Cancer Institute (NCI).

Mollica, who is a senior advisor in the NCI Office of Cancer Survivorship and is consequently responsible for developing, supporting, and promoting research efforts focused on cancer survivorship, gave a talk on individualized survivorship care plans at the 47th Annual Oncology Nursing Society Congress.

In an interview with Oncology Nursing News®, Mollica discusses tailoring different plans to fit the needs of different populations.

Related Content

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023

Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer

April 1st 2024

Article

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

June 1st 2023

Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer

March 26th 2024

Article

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer

March 25th 2024

Article

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.

Related Content

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023

Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer

April 1st 2024

Article

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

June 1st 2023

Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer

March 26th 2024

Article

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer

March 25th 2024

Article

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.